In vitro stability and metabolism of O2′, O3′, O5′-tri-acetyl-N⁶-(3-hydroxylaniline) adenosine in rat, dog and human plasma: Chemical hydrolysis and role of plasma esterases

References

• Aldridge W. (1993). The esterases perspectives and problems. Chem-Biol Interact, 87(1–3):5–13.
   PubMed Web of Science ®Google Scholar
• Anand S, Bruckner J, Haines W, Muralidhara S, Fisher J, Padilla S. (2006). Characterization of deltamethrin metabolism by rat plasma and liver microsomes. Toxicol Appl Pharm, 212(2):156–66.
   PubMed Web of Science ®Google Scholar
• Augustinsson K. (1959). Electrophoresis studied on blood plasma esterases I. mammalian plasmata. Acta Chem Scand, 13:571–92.
   Google Scholar
• Augustinsson K. (1961). Multiple forms of esterase in vertebrate blood plasma. Ann NY Acad Sci, 94:844–60.
   Web of Science ®Google Scholar
• Berry L, Wollenberg L, Zhao Z. (2009). Esterase activities in blood, liver and intestine of several preclinical species and humans. Drug Metab Lett, 3(2):70–7.
   PubMedGoogle Scholar
• Carmona G, Jufer R, Goldberg S, Gorelick D, Greig N, Yu Q, Cone E, Schindler C. (2000). Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab Disp, 28(3):367–71.
   PubMed Web of Science ®Google Scholar
• Cengiz D, Cokuğraş A, Kilinç K, Tezcan E. (1997). Histidine modification of human serum butyrylcholinesterase. Biochem Mol Med, 61(1):52–7.
   PubMedGoogle Scholar
• Chang Q, Chow M, Zuo Z. (2009). Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method. Biomed Chromatogr, 23(8):852–7.
   PubMed Web of Science ®Google Scholar
• Cokuğraş A, Cengiz D, Tezcan E. (2004). Do alkylating agents modify the histidine residue of the desensitized butyrylcholinesterase? Protein J, 23(8):495–500.
   PubMed Web of Science ®Google Scholar
• Cook C, Karabatsos P, Schoenhard G, Karim A. (1995). Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharm Res, 12(8):1158–64.
   PubMed Web of Science ®Google Scholar
• Dean R, Christian C, Sample R, Bosron W. (1991). Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J, 5(12):2735–9.
   PubMed Web of Science ®Google Scholar
• Draganov DI, La Du BN. (2004). Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol, 369(1):78–88.
   PubMed Web of Science ®Google Scholar
• Ericsson H, Tholander B, Regårdh C. (1999). In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci, 8(1):29–37.
   PubMed Web of Science ®Google Scholar
• Gonzalvo M, Gil F, Hernández A, Villanueva E, Pla A. (1997). Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem-Biol Interact, 105(3):169–79.
   PubMed Web of Science ®Google Scholar
• Heymann E, Krisch K. (1967). Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe-seyler’s Z. Physiol Chem, 348(6):609–19.
   PubMedGoogle Scholar
• Holm G, Kylberg-Hanssen K, Svensson L. (1985). Use of dodecyl sulfate as an esterase inhibitor before gas-chromatographic determination of labile β-adrenoceptor blocking drugs. Clin Chem, 31(6):368–70.
   Web of Science ®Google Scholar
• Inoue M, Morikawa M, Tsuboi M. (1979). Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs. Japan J Pharmacol, 29(1):9–16.
   PubMedGoogle Scholar
• Kluge W, Kluge H, Bauer H, Pietsch S, Anders J, Venbrocks R. (2001). Acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase. BMC Biochem, 2(17):1–8.
   PubMed Web of Science ®Google Scholar
• Koitka M, Höchel J, Gieschen H, Borchert H. (2010). Improving the ex vivo stability of drug ester compounds in rat and dog serum: Inhibition of the specific esterases and implications on their identity. J Pharmaceut Biomed, 51(3):664–78.
   PubMed Web of Science ®Google Scholar
• Kuo C, La Du B. (1998). Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos, 26(7):653–60.
   PubMed Web of Science ®Google Scholar
• Lawrence S, Melnick P, Weimer H. (1960). A species comparison of serum proteins and enzymes by starch gel electrophoresis. P Rel Maint S, 105:572–5.
   Google Scholar
• Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen E, Masson P, Lockridge O. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol, 70(11):1673–84.
   PubMed Web of Science ®Google Scholar
• Li W, Escarpe P, Eisenberg E, Cundy K, Sweet C, Jakema K, Merson J, Lew W, Williams M, Zhang L, and others. (1998). Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Ch, 42(3):647–53.
   PubMed Web of Science ®Google Scholar
• Liederer B, Borchardt R. (2005). Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J Pharm Sci-US, 94(10):2198–206.
   PubMed Web of Science ®Google Scholar
• Liederer B, Borchardt R. (2006). Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci-US, 95(6):1177–95.
   PubMed Web of Science ®Google Scholar
• Masaki K, Hashimoto M, Imai T. (2007). Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum. Drug Metab Dispos, 35(7):1089–95.
   PubMed Web of Science ®Google Scholar
• Minagawa T, Kohno Y, Suwa T, Tsuji A. (1995). Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol, 49(10):1361–5.
   PubMed Web of Science ®Google Scholar
• Minic J, Chatonnet A, Krejci E, Molgó J. (2003). Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Brit J Pharmacol, 138(1):177–87.
   PubMed Web of Science ®Google Scholar
• Minz G. (1993). An irreversible serine protease inhibitor. Biopharm, 6(2):34–8.
   Google Scholar
• Moriarty L, Lally M, Carolan C, Jones M, Clancy J, Gilmer J. (2008). Discovery of a “true” aspirin prodrug. J Med Chem, 51(24):7991–999.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, DeLuna P, Gorham L, Ma B, Cohn D, Pang J, Xu X, Leung K, Lin J. (1998). In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos, 26(6):520–7.
   PubMed Web of Science ®Google Scholar
• Saade M, Magdalou J, Ouaini N, Greige-Gerges H. (2009). Stability of cucurbitacin E in human plasma: chemical hydrolysis and role of plasma esterases. Biopharm Drug Dispos, 30(7):389–97.
   PubMed Web of Science ®Google Scholar
• Sarkarati B, Cokuğraş A, Tezcan E. (1999). Inhibition kinetics of human serum butyrylcholinesterase by Cd2+, Zn2+ and Al3+: comparison of the effects of metal ions on cholinesterases. Comp Biochem Physiology. Part C, Pharmacol Toxicol Endocrinol, 122(2):181–90.
   Web of Science ®Google Scholar
• Satoh T, Masakiyo H. (1998). The mammalian carboxylesterase: from molecules to functions. Annu Rev Pharmacol, 38:257–88.
   Google Scholar
• Senter P, Marquardt H, Thomas B, Hammock B, Frank I, Svensson H. (1996). The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res, 56(7):1471–4.
   PubMed Web of Science ®Google Scholar
• Tokumura T, Muraoka A, Masutomi T, Machida Y. (2005). Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. Biol Pharm Bull, 28(6):1126–8.
   PubMed Web of Science ®Google Scholar
• Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata Y, Inoue H. (2009). In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica, 39(5):391–8.
   PubMed Web of Science ®Google Scholar
• Wei R, Chu F. (1985). Modification of in vitro metabolism of T-2 toxin by esterase inhibitors. Appl Environ Microb, 50(1):115–9.
   PubMed Web of Science ®Google Scholar
• Williams F, Moore U, Seymour R, Mutch E, Nicholson E, Wright P, Wynne H, Blain P, Rawlins M. (1989). Benorylate hydrolysis by human plasma and human liver. Brit J Clin Pharmacol, 28(6):703–8.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, and others. (2006). Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinetics, 21(2):147–55.
   PubMed Web of Science ®Google Scholar
• Zeng J, Onthank D, Crane P, Unger S, Zheng N, Pasas-Farmer S, Arnold M. (2007). Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry− evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. J Chromatogr. B, Anal Technol Biomed Life Sci, 852(1–2):77–84.
   PubMed Web of Science ®Google Scholar